Show/Hide Menu

Proprietary Portfolio

The continued success of its partnered discovery segment provides MorphoSys with the adequate resources to channel substantial investment into proprietary R&D. Its in-house development organization focuses on the development of promising therapeutic antibody candidates in the area of inflammation and oncology. Learn more about the our programs which are in clinical evaluation:

Clinical Programs


MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism for tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
Further Information


In preclinical studies, MOR202 mediated antibody-dependent cell-mediated cytotoxicity in MM cells derived from patients in vitro.
Further Information


MOR103 (GSK3196165) is a fully human HuCAL antibody directed against GM-CSF (granulocytemacrophage-colony stimulating factor). MOR103 is being developed in the area of inflammatory diseases.
Further Information


MOR106 is a human IgG1 monoclonal antibody for treatment of inflammatory diseases.
Further Information